fda glp-1 compounding enforcement september 2025 is short-sighted on GLP-1s FDA Crackdown Puts Pressure on
Description
Ongoing research and patient education will further enhance our ability to address and mitigate these side effects, ensuring a better quality of life for those on this medication

In the STEP 1 trial, about 10% of participants achieved less than 5% weight loss, roughly the same as placebo response

GLP-1 receptors exist throughout the body, not just in the pancreas and hypothalamus, and activating them produces effects that extend far beyond metabolic signaling

[DOI] [PMC free article] [PubMed] [Google Scholar] 53.Shi X, Jiang A, Qiu Z, Lin A, Liu Z, Zhu L, et al

#Podiatry #GLP1 #DiabetesCare #FootHealth #Biomechanics #PatientEducation #HealthcareInnovation

however, their association with cancer risk remains a subject of ongoing debate
